Life-sciences and diagnostics company making analytical instruments (chromatography, mass spectrometry) and lab consumables/services.
Life-sciences and diagnostics company making analytical instruments (chromatography, mass spectrometry) and lab consumables/services.
Sells instruments once, then earns recurring revenue from the consumables, service contracts and software that run on them; the CrossLab arm handles that follow-on work. Pharmaceutical and chemical labs are the biggest buyers. It was spun out of Hewlett-Packard in 1999 and separated its electronics test business as Keysight in 2014.
Moat: narrow (installed base, switching costs, brand). Large installed instrument base drives recurring consumables and service revenue.
Headquarters: Santa Clara, California, USA · Founded: 1999 · Employees: 18,100
Size Agilent Technologies (A) is a United States Health Care company (Medical Specialties) with a market value of $50.0B, the 250th largest of 3,085 United States companies the cockpit tracks. Shares closed at $177.33 on 18 Nov 2026.
Performance Over six months the shares gained 56.1%, against +26.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 8.6% over the last twelve months (peer median +8.5%); the operating margin is 24.1% (peer median 20.4%).
Valuation It trades at 27.0× forward earnings against a peer median of 27.5× (10th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points above its cost of capital (10.9% WACC).
Backlog Backlog (remaining performance obligations) was $437M at 31 Oct 2025, up 7% on a year earlier — 0.1 years of trailing revenue. Backlog detail →
Credit Agilent Technologies has 6 bonds outstanding ($3.65B), rated BBB+ by the agencies and trading like A- at a weighted spread of 76 bp.
Short interest Short interest is 1.7% of the free float (30 Oct 2026).
Next results Next results expected around 23 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $7.37B | $6.95B | $6.51B | $6.83B | $6.85B |
| Revenue growth | — | +7% | -5% | 0% | — |
| Gross profit | $3.96B | $3.65B | $3.56B | $3.72B | $3.69B |
| EBITDA | $2.05B | $1.85B | $1.85B | $1.90B | $1.90B |
| Net income | $1.44B | $1.30B | $1.29B | $1.24B | $1.25B |
| Free cash flow | $1.27B | $1.15B | $1.37B | $1.47B | $1.02B |
| Capital expenditure | $342M | $407M | $378M | $298M | $291M |
| Total debt | $3.95B | $3.54B | $3.57B | $2.90B | $2.92B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Agilent Technologies A | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Waters WAT | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% |
| Shimadzu 7701.T | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | A | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | +7.3% | 6th lowest of 21 |
| 6-month return | +56.1% | +26.4% | 2nd highest of 21 |
| Distance from 52-week high | -3.1% | -8.3% | 4th highest of 21 |
| Revenue growth (TTM) | +8.6% | +8.5% | 11th highest of 21 |
| Operating margin | 24.1% | 20.4% | 7th highest of 21 |
| Forward P/E | 27.0× | 27.5× | 10th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 23.3% | 15.0% | 6th most demanding of 21 |
| Growth delivered (Del g) | +5.4% | +9.4% | 3rd lowest of 21 |
| Hurdle (Req g minus delivered) | +17.9 pp | +3.9 pp | 6th most demanding of 21 |
| ROIC minus cost of capital | +3.8 pp | +3.8 pp | 11th highest of 21 |
| EV / EBITDA | 25.5× | 19.1× | 8th most expensive of 20 |
| Net debt / EBITDA | 1.1× | 1.5× | 10th least indebted of 20 |
| Bond spread | 76 bp | 75 bp | 5th widest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| EssilorLuxottica EL.PA | France | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% | +14.6% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
Agilent Technologies has 6 bonds outstanding with $3.65B face value. The agencies rate it BBB+; its bonds trade like A-. Weighted yield 5.44%, a spread of 76 bp over government bonds.
Agilent Technologies reported $437M of remaining performance obligations at 31 Oct 2025, up 7% from a year earlier. That is 0.1 years of trailing revenue already under contract.